ZBIO
ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO
Delisted
ZBIO was delisted on the 27th of March, 2020.
6 hedge funds and large institutions have $701K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
$155K
Net Calls
-$155K
Net Calls Change
+$101K
Top Buyers
| 1 |
Jane Street
New York
|
$176K |
| 2 |
UBS Group
Zurich,
Switzerland
|
$55K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
$1K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
$3K |
| 2 |
VF
Virtu Financial
New York
|
$169K |
| 3 |
Citadel Advisors
Miami,
Florida
|
$297K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $297K | -$18K | -1,357 | -6% |
|
|
2
Jane Street
New York
| $176K | +$176K | +13,247 | New |
|
|
VF
3
Virtu Financial
New York
| $169K | -$36.3K | -2,739 | -18% |
|
|
4
UBS Group
Zurich,
Switzerland
| $55K | +$11.5K | +869 | +27% |
|
|
5
Morgan Stanley
New York
| $3K | -$85.2K | -6,362 | -97% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $1K | +$1K | +47 | New |
|